TVTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Travere Therapeutics Inc (TVTX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong growth potential driven by positive catalysts, such as significant revenue growth, promising drug developments, and favorable FDA updates. Despite some insider selling and net income decline, the long-term growth outlook and analyst optimism make it a compelling investment opportunity.
The MACD is positive at 0.17, indicating bullish momentum, though it is contracting. The RSI is neutral at 48.166, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot point of 29.347, with key resistance levels at 31.058 and 32.115, and support levels at 27.635 and 26.578.
FILSPARI sales grew 144% YoY in 2025, with a strong outlook for
FDA acceptance of supplemental NDA for FILSPARI in FSGS and a revised PDUFA date of April 13,
Resumption of the pivotal Phase III HARMONY study for pegtibatinase.
Analysts have raised price targets, with BofA maintaining a Buy rating and a target of $44.
Insider selling has increased by 125.53% in the last month.
Net income and EPS have significantly declined YoY, with net income dropping by -104.53%.
In Q4 2025, revenue increased by 73.41% YoY to $129.69 million, driven by strong FILSPARI sales. However, net income dropped by -104.53% YoY to $2.73 million, and EPS fell by -104.17% YoY to $0.03. Gross margin improved slightly to 98.03%, up 1.49% YoY.
Analysts are optimistic, with Piper Sandler raising the price target to $38 and BofA raising it to $44 with a Buy rating. Cantor Fitzgerald views FDA updates as a positive catalyst for Travere Therapeutics.
